Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Holding ANAB?
Track your performance easily
ANAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.70 - $41.31
Previous Close$24.96
Volume25.86K
Average Volume (3M)408.72K
Market Cap
$739.87M
Enterprise Value$345.88M
Total Cash (Recent Filing)$430.12M
Total Debt (Recent Filing)$16.49M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Feb 27, 2025EPS Estimate
-$1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.07
Shares Outstanding30,428,682
10 Day Avg. Volume458,245
30 Day Avg. Volume408,717
Standard Deviation0.21
R-Squared0.00337
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.33
Price to Sales (P/S)10.63
Price to Cash Flow (P/CF)-15.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.05
Enterprise Value/Gross Profit20.16
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$54.13Price Target Upside127.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
AnaptysBio News
PremiumCompany Announcements
AnaptysBio Reports Q3 2024 Financial Results and Updates
Bulls Say, Bears Say
Bulls Say
Financial PerformanceANAB reported a 3Q net loss of $32.9M, vs estimate of $43.6M and consensus at $46.1M.
Market OpportunityANB032 has a potential market opportunity of about $2 billion, assuming use in dupi experienced patients.
Product DifferentiationRosnilimab maintains a differentiated mechanism of action that has been followed by other companies and may be incorporated in future treatments.
Bears Say
Efficacy ConcernsConsensus expectations for success are low, because ANB032’s non-specific mechanism has yet to be validated in humans and may not deliver Dupixent-like efficacy.
Investor SentimentStreet's odds are low for rosnilimab, with essentially all the value for this program out of the stock.
Market PressureShares were pressured following LLY's termination of its PD-1 agonist program in RA, though we see the pullback as too severe given two upcoming Ph. II datasets and progress on the earlier pipeline.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $14.70 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Feb 27, 2025 which is in 86 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Nov 05, 2024. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.647 by $0.507.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.55.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,428,682 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.647. Following the earnings report the stock price went up 11.72%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 15M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.13 (127.92% Upside)
$54.13 (127.92% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 399.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 50.1%
Last 30 Days ▲ 50.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
62.53%
12-Months-Change
Fundamentals
Return on Equity
-161.81%
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$54.13
▲(127.92% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
-28.39%
reiterated a buy rating 22 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of -28.39% per trade.
---